Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Samuel Martel, Elena Poletto, Arlindo R Ferreira, Matteo Lambertini, Federico Sottotetti, Ilaria Bertolini, Filippo Montemurro, Antonio Bernardo, Emanuela Risi, Elisa Zanardi, Serena Ziliani, Silvia Mura, Chiara Dellepiane, Lucia Del Mastro, Alessandro Marco Minisini, Fabio Puglisi

Research output: Contribution to journalArticle

Abstract

Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight
Original languageUndefined/Unknown
Pages (from-to)142-147
Number of pages6
JournalBreast
Volume37
DOIs
Publication statusPublished - Feb 1 2018

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols, therapeutic use
  • Body Mass Index
  • Breast Neoplasms, drug therapy, metabolism, pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Metastasis
  • Proportional Hazards Models
  • Receptor, ErbB-2, metabolism
  • Retrospective Studies
  • Survival Rate
  • Trastuzumab, administration & dosage
  • Treatment Outcome
  • Body mass index
  • HER2-positive
  • Metastatic breast cancer
  • Trastuzumab

Cite this

Martel, S., Poletto, E., Ferreira, A. R., Lambertini, M., Sottotetti, F., Bertolini, I., Montemurro, F., Bernardo, A., Risi, E., Zanardi, E., Ziliani, S., Mura, S., Dellepiane, C., Del Mastro, L., Minisini, A. M., & Puglisi, F. (2018). Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast, 37, 142-147. https://doi.org/10.1016/j.breast.2017.11.004